New Rules on Local Production of Imported Drugs in China

June 03, 2024 | BY

Susan Mok

Fang Jianwei, Lv Chao and Yuan Chenhao of Zhong Lun Law Firm in Shanghai explain the background and impact – including on multinational companies – of a set of new rules governing the local production of imported drugs

Summary

  • New rules issued by the National Medical Products Administration aim to encourage the local production of certain pharmaceutical products
  • Chinese applicants are specifically targeted by the rules
  • Priority review and conditional approval procedures are applied under specific conditions by the rules
  • Multinational pharmaceutical companies are likely to find themselves impacted; finding local partners will be essential in some cases

 

 

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]